Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex
Although unmethylated CpG dinucleotide-containing oligodeoxynucleotides (CpG ODN) are able to inhibit tumor metastasis through the induction of antitumor immunity, their stability and delivery to antigen presenting cells needs to be improved. In this study, we formulated a CpG ODN complex with catio...
Gespeichert in:
| Veröffentlicht in: | Journal of controlled release 2006-10, Vol.115 (2), p.226-233 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 233 |
|---|---|
| container_issue | 2 |
| container_start_page | 226 |
| container_title | Journal of controlled release |
| container_volume | 115 |
| creator | Kuramoto, Yukari Nishikawa, Makiya Hyoudou, Kenji Yamashita, Fumiyoshi Hashida, Mitsuru |
| description | Although unmethylated CpG dinucleotide-containing oligodeoxynucleotides (CpG ODN) are able to inhibit tumor metastasis through the induction of antitumor immunity, their stability and delivery to antigen presenting cells needs to be improved. In this study, we formulated a CpG ODN complex with cationic liposomes (CpG ODN-lipoplex) and its antitumor activity was evaluated in peritoneal dissemination models of tumor cells stably labeled with firefly
luciferase gene. A single intraperitoneal administration of CpG ODN-lipoplex greatly reduced the number of tumor cells to 0.01% or lower compared with that detected in untreated mice, which may be associated with increased production of TNF-α and IL-12. CpG ODN-lipoplex increased the survival time of the tumor-bearing mice, and most long-term survivors rejected rechallenged tumor cells. These results indicate that a single dosing of CpG ODN-lipoplex is effective in inhibiting peritoneal dissemination and inducing long-lasting antitumor immunity. |
| doi_str_mv | 10.1016/j.jconrel.2006.08.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68974103</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365906003798</els_id><sourcerecordid>19457432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-df38f75f82f47e47cd9b6e999fc3601016a0e8e35dd5589af5674a31c03ac37b3</originalsourceid><addsrcrecordid>eNqFkcFu3CAQhq2qVbNJ-wituLQ3O2AMhlNVrdo0UqRe2jPCMCSsMLhgV8kL9LlrZzfKMYcRI_H9w8_8VfWB4IZgwi8PzcGkmCE0Lca8waLBuH1V7Yjoad1JyV5Xu5UTNeVMnlXnpRwwxox2_dvqjHApOeHtrvp3He_84GefIkoOTZD9nCLogKwvBUYf9dPdvIwpIwMhFDQ8oOLjbQBk09Y8au9SWct6KDNktJ-uUAr-NsXFBEizt3BpHod5g4KfUkkjIJPGKcD9u-qN06HA-9N5Uf3-_u3X_kd98_Pqev_1pjadxHNtHRWuZ060ruuh642VAwcppTOU420vGoMAyqxlTEjtGO87TYnBVBvaD_Si-nycO-X0Z1mNqtGX7Us6QlqK4kL2HcH0RZDIjvUdbVeQHUGTUykZnJqyH3V-UASrzZE6qFNSaktKYaHWpFbdx9MDyzCCfVadolmBTydAF6ODyzoaX5450RJBJV65L0cO1r399ZBVMR6iAeszmFnZ5F-w8h8tZLfi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19457432</pqid></control><display><type>article</type><title>Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kuramoto, Yukari ; Nishikawa, Makiya ; Hyoudou, Kenji ; Yamashita, Fumiyoshi ; Hashida, Mitsuru</creator><creatorcontrib>Kuramoto, Yukari ; Nishikawa, Makiya ; Hyoudou, Kenji ; Yamashita, Fumiyoshi ; Hashida, Mitsuru</creatorcontrib><description>Although unmethylated CpG dinucleotide-containing oligodeoxynucleotides (CpG ODN) are able to inhibit tumor metastasis through the induction of antitumor immunity, their stability and delivery to antigen presenting cells needs to be improved. In this study, we formulated a CpG ODN complex with cationic liposomes (CpG ODN-lipoplex) and its antitumor activity was evaluated in peritoneal dissemination models of tumor cells stably labeled with firefly
luciferase gene. A single intraperitoneal administration of CpG ODN-lipoplex greatly reduced the number of tumor cells to 0.01% or lower compared with that detected in untreated mice, which may be associated with increased production of TNF-α and IL-12. CpG ODN-lipoplex increased the survival time of the tumor-bearing mice, and most long-term survivors rejected rechallenged tumor cells. These results indicate that a single dosing of CpG ODN-lipoplex is effective in inhibiting peritoneal dissemination and inducing long-lasting antitumor immunity.</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2006.08.002</identifier><identifier>PMID: 16996162</identifier><identifier>CODEN: JCREEC</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Abdominal Cavity - pathology ; Animals ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; Cationic liposomes ; Cations - pharmacology ; Cell Line, Tumor ; Cell Transplantation ; Cholesterol ; CpG ODN ; Cytokines - biosynthesis ; Drug Carriers ; General pharmacology ; IL-12 ; Indicators and Reagents ; Interleukin-12 - biosynthesis ; Liposomes ; Macrophages - drug effects ; Macrophages - metabolism ; Male ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Oligonucleotides - administration & dosage ; Oligonucleotides - pharmacology ; Peritoneal cavity ; Peritoneal Cavity - pathology ; Peritoneal Lavage ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Quaternary Ammonium Compounds ; Survival ; Th1 Cells - drug effects ; Th1 Cells - metabolism ; TNF-alpha ; Tumor Necrosis Factor-alpha - biosynthesis</subject><ispartof>Journal of controlled release, 2006-10, Vol.115 (2), p.226-233</ispartof><rights>2006 Elsevier B.V.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-df38f75f82f47e47cd9b6e999fc3601016a0e8e35dd5589af5674a31c03ac37b3</citedby><cites>FETCH-LOGICAL-c490t-df38f75f82f47e47cd9b6e999fc3601016a0e8e35dd5589af5674a31c03ac37b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168365906003798$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18218390$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16996162$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuramoto, Yukari</creatorcontrib><creatorcontrib>Nishikawa, Makiya</creatorcontrib><creatorcontrib>Hyoudou, Kenji</creatorcontrib><creatorcontrib>Yamashita, Fumiyoshi</creatorcontrib><creatorcontrib>Hashida, Mitsuru</creatorcontrib><title>Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Although unmethylated CpG dinucleotide-containing oligodeoxynucleotides (CpG ODN) are able to inhibit tumor metastasis through the induction of antitumor immunity, their stability and delivery to antigen presenting cells needs to be improved. In this study, we formulated a CpG ODN complex with cationic liposomes (CpG ODN-lipoplex) and its antitumor activity was evaluated in peritoneal dissemination models of tumor cells stably labeled with firefly
luciferase gene. A single intraperitoneal administration of CpG ODN-lipoplex greatly reduced the number of tumor cells to 0.01% or lower compared with that detected in untreated mice, which may be associated with increased production of TNF-α and IL-12. CpG ODN-lipoplex increased the survival time of the tumor-bearing mice, and most long-term survivors rejected rechallenged tumor cells. These results indicate that a single dosing of CpG ODN-lipoplex is effective in inhibiting peritoneal dissemination and inducing long-lasting antitumor immunity.</description><subject>Abdominal Cavity - pathology</subject><subject>Animals</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cationic liposomes</subject><subject>Cations - pharmacology</subject><subject>Cell Line, Tumor</subject><subject>Cell Transplantation</subject><subject>Cholesterol</subject><subject>CpG ODN</subject><subject>Cytokines - biosynthesis</subject><subject>Drug Carriers</subject><subject>General pharmacology</subject><subject>IL-12</subject><subject>Indicators and Reagents</subject><subject>Interleukin-12 - biosynthesis</subject><subject>Liposomes</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Oligonucleotides - administration & dosage</subject><subject>Oligonucleotides - pharmacology</subject><subject>Peritoneal cavity</subject><subject>Peritoneal Cavity - pathology</subject><subject>Peritoneal Lavage</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Quaternary Ammonium Compounds</subject><subject>Survival</subject><subject>Th1 Cells - drug effects</subject><subject>Th1 Cells - metabolism</subject><subject>TNF-alpha</subject><subject>Tumor Necrosis Factor-alpha - biosynthesis</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu3CAQhq2qVbNJ-wituLQ3O2AMhlNVrdo0UqRe2jPCMCSsMLhgV8kL9LlrZzfKMYcRI_H9w8_8VfWB4IZgwi8PzcGkmCE0Lca8waLBuH1V7Yjoad1JyV5Xu5UTNeVMnlXnpRwwxox2_dvqjHApOeHtrvp3He_84GefIkoOTZD9nCLogKwvBUYf9dPdvIwpIwMhFDQ8oOLjbQBk09Y8au9SWct6KDNktJ-uUAr-NsXFBEizt3BpHod5g4KfUkkjIJPGKcD9u-qN06HA-9N5Uf3-_u3X_kd98_Pqev_1pjadxHNtHRWuZ060ruuh642VAwcppTOU420vGoMAyqxlTEjtGO87TYnBVBvaD_Si-nycO-X0Z1mNqtGX7Us6QlqK4kL2HcH0RZDIjvUdbVeQHUGTUykZnJqyH3V-UASrzZE6qFNSaktKYaHWpFbdx9MDyzCCfVadolmBTydAF6ODyzoaX5450RJBJV65L0cO1r399ZBVMR6iAeszmFnZ5F-w8h8tZLfi</recordid><startdate>20061010</startdate><enddate>20061010</enddate><creator>Kuramoto, Yukari</creator><creator>Nishikawa, Makiya</creator><creator>Hyoudou, Kenji</creator><creator>Yamashita, Fumiyoshi</creator><creator>Hashida, Mitsuru</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20061010</creationdate><title>Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex</title><author>Kuramoto, Yukari ; Nishikawa, Makiya ; Hyoudou, Kenji ; Yamashita, Fumiyoshi ; Hashida, Mitsuru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-df38f75f82f47e47cd9b6e999fc3601016a0e8e35dd5589af5674a31c03ac37b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Abdominal Cavity - pathology</topic><topic>Animals</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cationic liposomes</topic><topic>Cations - pharmacology</topic><topic>Cell Line, Tumor</topic><topic>Cell Transplantation</topic><topic>Cholesterol</topic><topic>CpG ODN</topic><topic>Cytokines - biosynthesis</topic><topic>Drug Carriers</topic><topic>General pharmacology</topic><topic>IL-12</topic><topic>Indicators and Reagents</topic><topic>Interleukin-12 - biosynthesis</topic><topic>Liposomes</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Oligonucleotides - administration & dosage</topic><topic>Oligonucleotides - pharmacology</topic><topic>Peritoneal cavity</topic><topic>Peritoneal Cavity - pathology</topic><topic>Peritoneal Lavage</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Quaternary Ammonium Compounds</topic><topic>Survival</topic><topic>Th1 Cells - drug effects</topic><topic>Th1 Cells - metabolism</topic><topic>TNF-alpha</topic><topic>Tumor Necrosis Factor-alpha - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuramoto, Yukari</creatorcontrib><creatorcontrib>Nishikawa, Makiya</creatorcontrib><creatorcontrib>Hyoudou, Kenji</creatorcontrib><creatorcontrib>Yamashita, Fumiyoshi</creatorcontrib><creatorcontrib>Hashida, Mitsuru</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuramoto, Yukari</au><au>Nishikawa, Makiya</au><au>Hyoudou, Kenji</au><au>Yamashita, Fumiyoshi</au><au>Hashida, Mitsuru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2006-10-10</date><risdate>2006</risdate><volume>115</volume><issue>2</issue><spage>226</spage><epage>233</epage><pages>226-233</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><coden>JCREEC</coden><abstract>Although unmethylated CpG dinucleotide-containing oligodeoxynucleotides (CpG ODN) are able to inhibit tumor metastasis through the induction of antitumor immunity, their stability and delivery to antigen presenting cells needs to be improved. In this study, we formulated a CpG ODN complex with cationic liposomes (CpG ODN-lipoplex) and its antitumor activity was evaluated in peritoneal dissemination models of tumor cells stably labeled with firefly
luciferase gene. A single intraperitoneal administration of CpG ODN-lipoplex greatly reduced the number of tumor cells to 0.01% or lower compared with that detected in untreated mice, which may be associated with increased production of TNF-α and IL-12. CpG ODN-lipoplex increased the survival time of the tumor-bearing mice, and most long-term survivors rejected rechallenged tumor cells. These results indicate that a single dosing of CpG ODN-lipoplex is effective in inhibiting peritoneal dissemination and inducing long-lasting antitumor immunity.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>16996162</pmid><doi>10.1016/j.jconrel.2006.08.002</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-3659 |
| ispartof | Journal of controlled release, 2006-10, Vol.115 (2), p.226-233 |
| issn | 0168-3659 1873-4995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68974103 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Abdominal Cavity - pathology Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacology Biological and medical sciences Cationic liposomes Cations - pharmacology Cell Line, Tumor Cell Transplantation Cholesterol CpG ODN Cytokines - biosynthesis Drug Carriers General pharmacology IL-12 Indicators and Reagents Interleukin-12 - biosynthesis Liposomes Macrophages - drug effects Macrophages - metabolism Male Medical sciences Mice Mice, Inbred C57BL Oligonucleotides - administration & dosage Oligonucleotides - pharmacology Peritoneal cavity Peritoneal Cavity - pathology Peritoneal Lavage Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Quaternary Ammonium Compounds Survival Th1 Cells - drug effects Th1 Cells - metabolism TNF-alpha Tumor Necrosis Factor-alpha - biosynthesis |
| title | Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T06%3A48%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20peritoneal%20dissemination%20of%20tumor%20cells%20by%20single%20dosing%20of%20phosphodiester%20CpG%20oligonucleotide/cationic%20liposome%20complex&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Kuramoto,%20Yukari&rft.date=2006-10-10&rft.volume=115&rft.issue=2&rft.spage=226&rft.epage=233&rft.pages=226-233&rft.issn=0168-3659&rft.eissn=1873-4995&rft.coden=JCREEC&rft_id=info:doi/10.1016/j.jconrel.2006.08.002&rft_dat=%3Cproquest_cross%3E19457432%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19457432&rft_id=info:pmid/16996162&rft_els_id=S0168365906003798&rfr_iscdi=true |